Intravitreal Aflibercept Injection as a Surgical Adjuvant in Severe Proliferative Diabetic Retinopathy
Overview
- Phase
- Phase 2
- Intervention
- Intravitreal Aflibercept Injection
- Conditions
- Vitreous Hemorrhage
- Sponsor
- University of Oklahoma
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Rate of Resolved Post-operative Vitreous Hemorrhage.
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
To evaluate the ocular and systemic safety of intravitreal aflibercept injection in patients undergoing Pars Plana Vitrectomy for Proliferative Diabetic Retinopathy.
Detailed Description
Patients who need Pars Plana Vitrectomy surgery, and agree to participate in this study will receive an injection of 2.0mg aflibercept 4 to 6 days before Vitrectomy surgery. Half of these patients will be randomized to receive another injection of 2.0mg aflibercept immediately after their surgery. Postoperative patient visits in this study will be at 1 day, and at weeks 1, 4, 16 and 24, and at any other times as deemed necessary by the Investigator.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Ability to provide written informed consent and comply with study assessments for the full duration of the study
- •Age \> 18 years
- •Diagnosed with proliferative diabetic retinopathy (PDR) requiring pars plana vitrectomy (PPV)
- •Best corrected visual acuity in the study eye between 20/40 to light perception (LP) using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart
Exclusion Criteria
- •Pregnancy (positive urine pregnancy test) or lactation
- •Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an intrauterine device (IUD), or contraceptive hormone implant or patch.
- •Participation in a study of an investigational drug or device within the past 30 days prior to enrolling in the study
- •For previously treated subjects -
- •Prior treatment with anti-vascular endothelial growth factor (anti-VEGF) therapy in the study eye within 28 days of Screening
- •Prior treatment with triamcinolone in the study eye within 6 months of Screening.
- •Prior treatment with dexamethasone in the study eye within 30 days of Screening
- •Intraocular surgery (including cataract surgery) in the study eye within 2 months preceding Baseline
- •History of vitrectomy surgery, submacular surgery, or other surgical intervention for PDR in the study eye
- •Active intraocular inflammation (grade trace or above) in the study eye
Arms & Interventions
Vitrectomy with Aflibercept Injection
Preoperative 2.0mg intravitreal aflibercept and vitrectomy with intraoperative 2.0mg intravitreal aflibercept injection.
Intervention: Intravitreal Aflibercept Injection
Standard Vitrectomy
Preoperative 2.0mg intravitreal aflibercept and standard of care vitrectomy.
Intervention: Standard Vitrectomy
Outcomes
Primary Outcomes
Rate of Resolved Post-operative Vitreous Hemorrhage.
Time Frame: 24 weeks
Percentage of patients who had no vitreous hemorrhage before or at week 24
Secondary Outcomes
- Mean Change in Visual Acuity(24 weeks)
- Need for Any Additional Surgical Intervention.(24 weeks)
- Changes in Mean Central Retinal Thickness.(24 weeks)